2026-04-17T15:54:18Zhttps://recercat.cat/oai/request

oai:recercat.cat:11351/127132025-10-24T10:40:53Zcom_2072_378070com_2072_378040col_2072_378092

Parameningeal Rhabdomyosarcoma: Results of the European Pediatric Soft Tissue Sarcoma Study Group RMS 2005 Study Schoot, Reineke Anna Taselaar, Pieter Michael Kolb, Frederic ter Horst, Simone Hladun Alvaro, Raquel Scarzello, Giovanni Coppadoro, Beatrice Infants Tumors de parts toves - Tractament Músculs - Càncer - Prognosi Avaluació de resultats (Assistència sanitària) DISEASES::Neoplasms::Neoplasms by Histologic Type::Neoplasms, Connective and Soft Tissue::Neoplasms, Muscle Tissue::Myosarcoma::Rhabdomyosarcoma Other subheadings::Other subheadings::/therapy ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Diagnosis::Prognosis DISEASES::Neoplasms::Neoplasms by Site::Nervous System Neoplasms::Central Nervous System Neoplasms::Meningeal Neoplasms Other subheadings::Other subheadings::/therapy NAMED GROUPS::Persons::Age Groups::Child ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Diagnosis::Prognosis::Treatment Outcome ENFERMEDADES::neoplasias::neoplasias por tipo histológico::neoplasias de tejido conjuntivo y de tejidos blandos::neoplasias de tejido muscular::miosarcoma::rabdomiosarcoma Otros calificadores::Otros calificadores::/terapia TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::diagnóstico::pronóstico ENFERMEDADES::neoplasias::neoplasias por localización::neoplasias del sistema nervioso::neoplasias del sistema nervioso central::neoplasias meníngeas Otros calificadores::Otros calificadores::/terapia DENOMINACIONES DE GRUPOS::personas::Grupos de Edad::niño TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::diagnóstico::pronóstico::resultado del tratamiento Head and neck; Prognostic risk factors; Rhabdomyosarcoma Cabeza y cuello; Factores de riesgo pronóstico; Rabdomiosarcoma Cap i coll; Factors de risc pronòstic; Rabdomiosarcoma Background Parameningeal (PM) site is an unfavorable characteristic in rhabdomyosarcoma (RMS). We described the treatment and outcome for patients with PM RMS and investigated the prognostic value of risk factors. We scored PM site by originating site and by highest risk extension. Methods Patients with PM RMS were treated within the European pediatric Soft tissue sarcoma Study Group (EpSSG) RMS 2005 study with risk-adapted, multi-modal treatment. Results Three-hundred-eighty-one patients with PM RMS were included. Radiotherapy was administered in 359 patients (77 with surgery). After a median follow-up of 75 months, 5-year event-free survival was 60% (95% confidence interval (CI) 55%–65%), 5-year overall survival was 65% (95% CI 60%–70%). Conclusions The outcome for patients with PM RMS has not improved in comparison to previous historical studies, despite the more rigorous application of radiotherapy (94% of patients). Signs of meningeal involvement, PM site, and age at diagnosis remained prognostic risk factors. Trial Registration EudraCT number 2005-000217-35 This work was supported by Royal Marsden Cancer Charity, Alice's Arc, children's cancer charity, and NIHR Biomedical Research Centre, Royal Marsden NHS Foundation Trust/Institute of Cancer Research. 2025-10-24T10:40:53Z 2025-10-24T10:40:53Z 2025-10-24T10:40:53Z 2025-03-07T11:39:04Z 2025-03-07T11:39:04Z 2025-03 info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion http://hdl.handle.net/11351/12713 Head & Neck;47(3) https://doi.org/10.1002/hed.27994 Attribution-NonCommercial-NoDerivatives 4.0 International http://creativecommons.org/licenses/by-nc-nd/4.0/ info:eu-repo/semantics/openAccess Wiley Scientia